Blood Cancer Awareness Month: highlighting our open access blood cancer research
To mark Blood Cancer Awareness Month, our editors across a number of open access oncology journals have developed a collection of articles to showcase some of the latest research in the field. We’ve also created a blood cancer morphology quiz to help visualize the different types of blood cancers. Let us know what you think of the research or the quiz @OncoBioMed #BloodCancerAwarenessMonth.
© Kateryna_Kon / stock.adobe.com
September marks Blood Cancer Awareness Month. In recognition of this, we are proud to present some of our research on blood cancer that has been published within the open access oncology journal portfolio.
Blood cancer encompasses many different hematological disorders that affect the blood, bone marrow and/or lymphatic system. The different types of blood cancer can be grouped into the following categories: leukemia, lymphoma or myeloma. It is estimated that in the US, a person is diagnosed with blood cancer every three minutes. Leukemia is a global problem and is currently ranked the 13th most common cancer worldwide.
If you would like to go back to basics with an overview of the classification and laboratory investigation of blood cancers, click here to read our ‘Blood cancer in a nutshell: Classification and investigation’ blog.
As a global health issue, continued research on blood cancer is of paramount significance with particular reference to risk assessment and prognostics, diagnostics, genetics, clinical trials and therapeutics. The articles in this collection have been curated by our oncology journal editors and include some of the latest research in the field in each of these categories.
Risk assessment and prognostics
Association of elevated serumfree light chains with chronic lymphocytic leukemia and monoclonal B-cell lymphocytosis
Clinical predictors of long-term survival in newly diagnosed transplant eligible multiple myeloma — an IMWG Research Project
Down-regulation of miR-29c is a prognostic biomarker in acute myeloid leukemia and can reduce the sensitivity of leukemic cells to decitabine
Late relapse in acute myeloid leukemia (AML): clonal evolution or therapy-related leukemia?
Management of cardiovascular risk in patients with multiple myeloma
Polyclonal serum free light chain elevation is associated with increased risk of monoclonal gammopathies
The assessment of minimal residual disease versus that of somatic mutations for predicting the outcome of acute myeloid leukemia patients
Challenges in the introduction of next-generation sequencing (NGS) for diagnostics of myeloid malignancies into clinical routine use
Elevated IgM and abnormal free light chain ratio are increased in relatives from high-risk chronic lymphocytic leukemia pedigrees
Identification of ADGRE5 as discriminating MYC target between Burkitt lymphoma and diffuse large B-cell lymphoma
Lymphopenia at diagnosis is highly prevalent in myelodysplastic syndromes and has an independent negative prognostic value in IPSS-R-low-risk patients
Molecular tumor analysis and liquid biopsy: a feasibility investigation analyzing circulating tumor DNA in patients with central nervous system lymphomas
Role of microRNAs, circRNAs and long noncoding RNAs in acute myeloid leukemia
T cell senescence and CAR-T cell exhaustion in hematological malignancies
A modular transcriptome map of mature B cell lymphomas
Amplification of 9p24.1 in diffuse large B-cell lymphoma identifies a unique subset of cases that resemble primary mediastinal large B-cell lymphoma
An acquired high-risk chromosome instability phenotype in multiple myeloma: Jumping 1q Syndrome
An age-based, RNA expression paradigm for survival biomarker identification for pediatric neuroblastoma and acute lymphoblastic leukemia
Deciphering the chronology of copy number alterations in Multiple Myeloma
Distinct promoter methylation profile reveals spatial epigenetic heterogeneity in 2 myeloma patients with multifocal extramedullary relapses
Epigenetic silencing of miR-340-5p in multiple myeloma: mechanisms and prognostic impact
Genetic correlation between multiple myeloma and chronic lymphocytic leukaemia provides evidence for shared aetiology
Genomic and epigenomic predictors of response to guadecitabine in relapsed/refractory acute myelogenous leukemia
Identification of genetic association between cardiorespiratory fitness and the trainability genes in childhood acute lymphoblastic leukemia survivors
Immunoglobulin gene rearrangement IGHV3-48 is a predictive marker of histological transformation into aggressive lymphoma in follicular lymphomas
Long non-coding RNAs in hematological malignancies: translating basic techniques into diagnostic and therapeutic strategies
Mutational processes contributing to the development of multiple myeloma
The anticancer effects of MPT0G211, a novel HDAC6 inhibitor, combined with chemotherapeutic agents in human acute leukemia cells
A randomised phase II trial of selinexor with cyclophosphamide and prednisolone in relapsed or refractory multiple myeloma (RRMM) patients
Interpreting clinical trial data in multiple myeloma: translating findings to the real-world setting
PERCEPT – myeloma transplant prehab study
RIVA – a phase IIa study of rituximab and varlilumab in relapsed or refractory B-cell malignancies: study protocol for a randomized controlled trial
Current status of autologous stem cell transplantation for multiple myeloma
EZH2 as a therapeutic target for multiple myeloma and other haematological malignancies
Functional diversity of inhibitors tackling the differentiation blockage of MLL-rearranged leukemia
Inotuzumab ozogamicin in clinical development for acute lymphoblastic leukemia and non-Hodgkin lymphoma
Integrating precision medicine through evaluation of cell of origin in treatment planning for diffuse large B-cell lymphoma
Micafungin prophylaxis for acute leukemia patients undergoing induction chemotherapy
Novel and emerging therapies for B cell lymphoma
Super-enhancers: critical roles and therapeutic targets in hematologic malignancies
Targeting CLL-1 for acute myeloid leukemia therapy
The journey to CAR T cell therapy: the pediatric and young adult experience with relapsed or refractory B-ALL
Articles from the following journals have been included in this collection: Biomarker Research / BMC Cancer / Cancer Cell International / Clinical Epigenetics / Blood Cancer Journal / Genome Medicine / ISRCTN Registry / Journal of Hematology & Oncology / Trials
Now that you have read the research, why not test your knowledge of blood cancer morphology with our Blood Cancer Quiz?